2008•Zhongguo tangniaobing zazhiRequires access

Rosiglitazone therapy ameliorates endotheliocyte dysfunction in pre-diabetes

Feng Ping

Abstract

After treatment of pre-diabetic patients with rosiglitazone (Avandia 4mg/d) for 12 weeks,the levels of fasting glucose(4.9±0.5 vs .6.2±0.7,P0.001) and insulin (7.4±1.9 vs.12.7±2.4,P0.001) were decreased,and endothelium-dependent vasodilation (EDV) (9.2±2.6 vs.7.9±2.5,P0.05) and nitric oxide (NO) (53.2±19.3 vs.43.7±12.5,P0.05) were increased as compared with control group, indicating that rosiglitazone ameliorates endothelial dysfunction probably through NO release.

About this research paper

What this paper is about

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Rosiglitazone, Medicine, Internal medicine, Diabetes mellitus, Endothelial dysfunction, Nitric oxide, Endocrinology, Vasodilation